Apretude (Cabotegravir) Patent Expiration, LOE Window & CMS Spending

Apretude (Cabotegravir) by GSK: FDA Orange Book core substance LOE 2031-02-04 (last listed 2031-09-15), 0 AB generics, $89.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN215499 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-02-04
Last Listed Patent or Exclusivity Date2031-09-15
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$89.7M
2024 Medicare Part D Spend$12.8M
2024 Medicaid Spend$76.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.